The use of intermediate endpoints in the design of type 1 diabetes prevention trials
- 7 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 56 (9), 1919-1924
- https://doi.org/10.1007/s00125-013-2960-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2011
- The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial resultsPediatric Diabetes, 2009
- Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2008
- Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR)Pediatric Diabetes, 2007
- Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2006
- Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic SubjectsDiabetes Care, 2005
- Effects of Oral Insulin in Relatives of Patients With Type 1 DiabetesDiabetes Care, 2005
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Type 1 diabetes: new perspectives on disease pathogenesis and treatmentThe Lancet, 2001
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958